Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections

Clinical Evidence in Respiratory and Urinary Tract Infections: Focus on Ceftibuten

Abstract Background Antimicrobial resistance (AMR) is one of the most pressing global health problems, resulting from the misuse and overuse of antibiotics across various sectors, which has led to the emergence and spread of resistant microorganisms. AMR occurs when microorganisms no longer respond to antibiotics. In I...

QUALITY IN

This narrative review synthesizes current clinical and microbiological evidence regarding nitroxoline's mechanism of action, pharmacokinetics, safety profile, and resistance rates, and evaluates the drug's therapeutic positioning across updated international clinical guidelines published up to May 2026.

The Direct and Potentiating Antimicrobial Activities of Zafirlukast

It is established that Zafirlukast has activities beyond Mycobacterium and Gingivalis, encompassing many Gram-positive bacteria including MRSA, and, for the first time, its putative target is reported as LtaS, of which there are no currently approved inhibitors.

Revisiting the mode of action of daptomycin considering the inoculum effect and a novel liposome-MIC-competition assay.

Daptomycin (DAP) is a cyclic lipopeptide drug for intravenous application against Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). In spite of numerous studies, its mode of action remains controversial. This is partially due to the fact that no attention has been paid to the strong dep...

Engineering lipopeptide-gramicidin S conjugates to combat multidrug-resistant Acinetobacter baumannii and other ESKAPE pathogens.

Novel Gramicidin S analogues demonstrated broad-spectrum antibacterial activity against WHO priority pathogens, thus highlighting their potential as promising candidates for further therapeutic development.

The efficacy and safety of omadacycline plus β-lactam versus moxifloxacin plus β-lactam for the treatment of severe community-acquired pneumonia: study protocol of a multicenter, prospective, randomized controlled non-inferiority trial.